After nearly 60 years on the U.S. market, benzodiazepine risks were 'officially' recognized by the FDA, necessitating changes in Boxed Warning language.  This information was not widely disseminated to healthcare providers, pharmacists, or patients.  Additionally, there is no widely accepted benzodiazepine guideline(s) in the U.S. that is used unequivocally across patient care settings that define rational use and protocols for de-prescribing.  This presentation will identify commonalities across multiple rational-use and best practice guidelines, identify the necessity of informed consent, and review a number of evidence-based de-prescribing strategies.